Literature DB >> 1899011

Clenbuterol plus acivicin decrease tumor growth and increase muscle mass in rats maintained on total parenteral nutrition.

W T Chance1, L Cao, F S Zhang, J E Fischer.   

Abstract

Two problems associated with supplemental nutrition of tumor-bearing organisms are control of tumor growth and reduction of cachexia. To investigate these problems, rats bearing methylcholanthrene-induced sarcomas were maintained on total parenteral nutrition (TPN) for 10 to 12 days beginning 23 days after tumor inoculation. Combined treatment of one group of these rats with the glutamine antimetabolite, acivicin, and the beta 2-adrenergic agonist, clenbuterol, arrested tumor growth, increased skeletal muscle mass and protein content, increased gut mass, and decreased total plasma lipid levels. Resting energy expenditure and cardiac mass were increased by TPN and were increased further by acivicin plus clenbuterol. These results demonstrate that tumor growth and muscle wasting can be controlled during TPN of tumor-bearing organisms. Therefore, cachectic depletion of lean body tissue may not be obligatory in neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899011     DOI: 10.1016/0002-9610(91)90360-p

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Protein metabolism in guanethidine-treated rats.

Authors:  Milan Holecek; Marcela Bielavská; Ludek Sprongl
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

2.  Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock.

Authors:  B K Winter; G Fiskum; L L Gallo
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

Review 3.  Review of Mechanisms and Treatment of Cancer-Induced Cardiac Cachexia.

Authors:  Vignesh Vudatha; Teja Devarakonda; Christopher Liu; Devon C Freudenberger; Andrea N Riner; Kelly M Herremans; Jose G Trevino
Journal:  Cells       Date:  2022-03-18       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.